Hu Liu

Hu is the Director of Medicinal Chemistry. Hu has 19 years of small molecule drug discovery experience in biotech, large pharma, and academic institutions. Prior to joining Avilar, Hu was at the Center for Protein Degradation (CPD) at the Dana-Farber Cancer Institute where he led cereblon-based degrader projects for oncology treatments. Earlier in his career, Hu held positions with increasing responsibilities at Amgen, ImClone, Pfizer, and Crown Bioscience (China), working on a range of therapeutic areas including oncology, osteoporosis and immunology. Hu is a co-author/co-inventor of 38 peer reviewed publications and patents.

He received his PhD from Temple University and completed postdoctoral training at the University of Pennsylvania.